KR920011485A - 발포 h₂차단제 제제를 이용하여 타는듯하고 쓰린속이나 위산과다와 관련된 위장병을 치료하는 방법 - Google Patents

발포 h₂차단제 제제를 이용하여 타는듯하고 쓰린속이나 위산과다와 관련된 위장병을 치료하는 방법 Download PDF

Info

Publication number
KR920011485A
KR920011485A KR1019910023427A KR910023427A KR920011485A KR 920011485 A KR920011485 A KR 920011485A KR 1019910023427 A KR1019910023427 A KR 1019910023427A KR 910023427 A KR910023427 A KR 910023427A KR 920011485 A KR920011485 A KR 920011485A
Authority
KR
South Korea
Prior art keywords
blocker
composition
foamed
burning
transport system
Prior art date
Application number
KR1019910023427A
Other languages
English (en)
Inventor
폴로스 맨리 에이
Original Assignee
스티븐 비. 페이지
마일즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스티븐 비. 페이지, 마일즈 인코포레이티드 filed Critical 스티븐 비. 페이지
Publication of KR920011485A publication Critical patent/KR920011485A/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

내용 없음

Description

발포 H2차단제 제제를 이용하여 타는듯하고 쓰린속이나 위산과다와 관련된 위장병을 치료하는 방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1a도는 디미프릿으로 전처리하고 물을 먹인 (○표) 개들과 0.3㎎/㎏의 라니티딘만을 먹인 (●표)개들의 위의 pH의 시간(분단위)적 추이를 도시한 것이고, 제1b도는 디미프릿전처리한 개들중에서 0.3㎎/㎏의 라니티딘과 함께 8mEq(▲표)의 산증화농을 가진 발포성분들을 먹인 개들의 위의 pH의 시간(분단위)적 추이를 물만 먹인 개들의 것과 비교도시한 것이다.

Claims (12)

  1. a, 수용성 H2차단제와 발포성수송제를 포함하는 조성물을 물에 용해시키고, b, 타는듯하고 쓰린속 또는 위산과다에 관련된 위장병으로 고통받는 사람에게 상기 용액을 경우투여하여, 즉각적이고 지속적인 경감을 약 1∼3시간 동안 제공하는 단계들을 포함ㅎ여, 위장병으로 고통받는 사람을치료하는 방법.
  2. 제1항에 있어서, H2차단제가 라니티딘, 파모티딘, 시메티딘 및 니자티딘으로 이루어지는 그룹중에서 선택되는 방법.
  3. 제1항에 있어서, 발포수송계의 산중화능력이 약 3 내지 약 40mEq범위내인 방법.
  4. 제1항에 있어서, 조성물이 활성십이지장궤양의 1일 2회 치료법에 대해 처방되는 용량의 약 25% 미만인 양의 H2차단제를 함유하는 방법.
  5. 제4항에 있엇, 조성물이 활성십이지장궤양의 1일 2회 치료법에 대해 처방되는 용량의 약 5 내지 20% 범위의 양의 H2차단제를 함유하는 방법.
  6. 제4항에 있어서, H2차단제가 라니티딘, 파모티딘, 시메티딘 및 니자티딘으로 이루어진 그룹중에서 선택되는 방법.
  7. 제4항에 있어서, 발포수송계의 산중화능력이 약 3 내지 약 40mEq 범위인 방법.
  8. a. 수용성 H2차단제(여기서, H2차단제의 양은 활성십이지장궤양의 1일 2회 치료법에 대한 처방용량의 약 25%미만임), 및 b. 발포수송계를 포함하며, 물에 용해시켜 사람에게 경구투여할 경우, 약 1 내지 3시간동안 즉각적이고 지속적인 경감을 제공하는, 타는듯하고 쓰린속 또는 위산과다와 관련된 위장병으로 고통받는 사람을 치료하기 위한 조성물.
  9. 제8항에 있어서, H2차단제의 양이 활성십이지장궤양의 1일 2회 치료법에 대한 처방용량의 약 5 내지 약 20% 범위내인 조성물.
  10. 제8항에 있어서, H2차단제가 라니티딘, 파모티딘, 시메티딘 및 니자티딘으로 구성된 그룹중에서 선택되는 조성물.
  11. 제8항에 있어서, 발포수송계의 산중화능력이 약 3 내지 약 40mEq 범위인 조성물.
  12. 제8항에 있어서, 정제형태인 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019910023427A 1990-12-21 1991-12-19 발포 h₂차단제 제제를 이용하여 타는듯하고 쓰린속이나 위산과다와 관련된 위장병을 치료하는 방법 KR920011485A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63323090A 1990-12-21 1990-12-21
US07/633,230 1990-12-21

Publications (1)

Publication Number Publication Date
KR920011485A true KR920011485A (ko) 1992-07-24

Family

ID=24538793

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019910023427A KR920011485A (ko) 1990-12-21 1991-12-19 발포 h₂차단제 제제를 이용하여 타는듯하고 쓰린속이나 위산과다와 관련된 위장병을 치료하는 방법

Country Status (5)

Country Link
EP (1) EP0492247A1 (ko)
JP (1) JPH0539219A (ko)
KR (1) KR920011485A (ko)
AU (1) AU8989391A (ko)
CA (1) CA2055661A1 (ko)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
GB9407235D0 (en) * 1994-04-12 1994-06-08 Glaxo Group Ltd Pharmaceutical compositions
WO1996002262A2 (en) * 1994-07-20 1996-02-01 American Home Products Corporation Pharmaceutical compositions for the treatment of gastrointestinal distress comprising h2 receptor antagonists and antacids
US5470865A (en) * 1994-08-30 1995-11-28 Eli Lilly And Company Pharmaceutical composition
US5667794A (en) * 1995-05-02 1997-09-16 Merck & Co., Inc. Heartburn treatment
US5854267A (en) * 1995-06-02 1998-12-29 Merck & Co., Inc. Method for preventing heartburn
US5989588A (en) * 1996-10-04 1999-11-23 Merck & Co., Inc. Methods and compositions for preventing and treating heartburn
ES2274550T3 (es) * 1996-10-04 2007-05-16 MERCK & CO., INC. Procedimientos y composiciones para prevenir y tratar ardor de estomago.
WO2017091166A1 (en) 2015-11-26 2017-06-01 Pharmacti̇ve İlaç San. Ve Ti̇c. A.Ş. Stable pharmaceutical compositions and process for their preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2593065B1 (fr) * 1986-01-22 1988-09-09 Smith Kline French Lab Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation.
FR2633181B1 (fr) * 1988-06-24 1992-01-10 Glaxo Lab Sa Composition pharmaceutique a base de ranitidine et son procede de preparation
FR2648710B1 (fr) * 1989-06-23 1994-01-14 Glaxo Sa Laboratoires Composition pharmaceutique a base de ranitidine et son procede de preparation

Also Published As

Publication number Publication date
CA2055661A1 (en) 1992-06-22
JPH0539219A (ja) 1993-02-19
AU8989391A (en) 1992-06-25
EP0492247A1 (en) 1992-07-01

Similar Documents

Publication Publication Date Title
US4945083A (en) Safe oral folic-acid-containing vitamin preparation
JP2002543106A (ja) 抗悪心組成物および方法
IE903931A1 (en) Pharmaceutical compositions for treating gastrointestinal distress
KR910019618A (ko) 발기부전증 치료용 제약 조성물
KR920011485A (ko) 발포 h₂차단제 제제를 이용하여 타는듯하고 쓰린속이나 위산과다와 관련된 위장병을 치료하는 방법
EP0651993A4 (en) BASIC COMPOSITION ADMINISTERABLE BY PERCUTANEOUS INJECTION AND DERIVATIVE MEDICINAL COMPOSITION.
GB2089660A (en) Cobalt compound-containing preparations for arthritis treatment
Kratz et al. Post-ingestive effects of quinine on intake of nutritive and non-nutritive substances
DUPONT et al. Chemotherapy and chemoprophylaxis of travelers' diarrhea
PT891186E (pt) Administração nasal de agentes para o tratamento de emese tardia
EP0261693A1 (en) Treated lipid regulator
KALES et al. Effect of divided calcium intake on calcium metabolism
US5948824A (en) Use of a chemical agent for reducing the changes in waistline and the effect of constipation due to the taking of other agents
Steven et al. Does the order of second-line treatment in rheumatoid arthritis matter?
CA1208132A (en) Composition for relieving toothache pain and other forms of intense pain
DesGroseilliers et al. Pellagra.
CA2184361C (en) Solid dose forms containing bismuth
US4446132A (en) Nontoxic aspirin composition
Fishler Effects of aspirin, acetaminophen, and salicylamide on gastric mucosa of dogs
US3055805A (en) Process of treating acidosis with t.h.a.m.
Mellinger et al. Primary polydipsia: syndrome of inappropriate thirst
JPH0232020A (ja) モルフィン鎮痛治療における耐性発現の抑制方法および薬剤
AU629520B2 (en) A medicament
JPH0240045B2 (ko)
RU2026673C1 (ru) Средство для лечения энуреза

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid